Previous 10 | Next 10 |
Alkermes plc (ALKS) Q3 2022 Earnings Conference Call November 02, 2022, 08:00 AM ET Company Participants Sandra Coombs - SVP, IR & Corporate Affairs Richard Pops - CEO Iain Brown - CFO Todd Nichols - CCO Conference Call Participants Umer Raffa...
Alkermes ( NASDAQ: ALKS ) is exploring breaking off its development-stage oncology business into a separately traded company. The company said that a separation would support a strategic focus for each business, establish distinct management teams, and simplify capital all...
Alkermes press release ( NASDAQ: ALKS ): Q3 Non-GAAP EPS of $0.02 misses by $0.01 . Revenue of $252.36M (-14.2% Y/Y) misses by $19.09M . The company expects total revenue to be between $1.07B and $1.12B vs. prior view of $1.05B to $1.12B and consensus of $...
Alkermes plc Reports Third Quarter 2022 Financial Results PR Newswire — Third Quarter Revenues of $252.4 Million Reflect Strong Year-Over-Year Growth of Proprietary Commercial Product Portfolio — — GAAP Loss per Share of $0.39 and N...
Alkermes plc Announces Intent to Separate Oncology Business PR Newswire — Alkermes to Focus on Profitable Growth of Pure-Play, Commercial-Stage Neuroscience Business — — Separation Expected to Unlock Value Through Sharpened Strategic Focus,...
Alkermes Announces Recipients of 2022 Alkermes Inspiration Grants® Program PR Newswire – 6 th Installment of Competitive Grants Program Awards Funding to Nine Innovative Programs Focused on People Living with Addiction, Serious Mental Illness or Can...
Alkermes to Report Third Quarter Financial Results on Nov. 2, 2022 PR Newswire DUBLIN , Oct. 26, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 12:00 p.m. GMT ) on Wedn...
BofA Securities has upgraded Alkermes to hold from underperform as it sees peak sales of ~$650M from bipolar disorder treatment Lybalzi (olanzapine and samidorphan). The firm, however, lowered its price target to $25 from $27 (10% upside based on Thursday's close). Analyst Jas...
Akermes ( NASDAQ: ALKS ) shareholder Sarissa Capital disclosed that it may seek to raise its stake in the biohpharma company. Sarissa, which owns ~14 million shares, or a 8.55% stake, said that it intends "to enhance the buying power in one of its concentrated accounts by ...
Alkermes Announces Launch of 5th Annual Alkermes Pathways Research Awards® Program PR Newswire -- Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project -- -- Application Period Open Until Nov. 30, 2022 -- DUBL...
News, Short Squeeze, Breakout and More Instantly...
Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, ...
2024-06-29 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-19 17:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...